Terumo Medical Corporation, a wholly-owned subsidiary of Terumo Corporation, announced the U.S. launch of its SurTract™ Safety Syringe, powered by SafeR® passive safety technology developed by Roncadelle Operations S.r.l. The SurTract Syringe will be distributed across hospitals, clinics, and emergency-care settings beginning in the first quarter of 2026.
SafeR technology provides the SurTract Syringe with a fully passive, automatic retraction mechanism that withdraws the needle into the plunger immediately after use – helping reduce the risk of needle-stick injuries for physicians, and providing patients with a smooth and comfortable injection due to less plunger pressure*. The syringe system also preserves standard clinical technique while offering enhanced safety, reliability, and ease of use.
"The SurTract Syringe combines Terumo's trusted clinical know-how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections," says Bob Klock, Vice President, Terumo Medical Corporation. "It gives healthcare providers more – and better – treatment options for their patients, which is our ultimate goal."
Other benefits include:
- A customizable needle selection designed for use exclusively with SurTract Syringes, allowing physicians the opportunity to create the combination they need for optimal patient care.
- A blunt needle, preventing dullness and allowing a change of needle for drawing up aspiration.
- Less medical waste due to a lack of an external plastic safety sheath.
- Reduction in medication waste due to the low dead space syringe*.
"Terumo has significantly advanced injection safety with the integration of our SafeR technology," says Dr. Fred Metzmann, Chief Business Development Officer at Roncadelle Operations. "Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals."
*Data on file
